19 年前 -
Image: CARY WOLINSKY (photograph); JEN CHRISTIANSEN (photoillustration) CHILDREN WITH AUTISM may struggle with social interaction because their mirror neuron systems are not functioning properly. At first glance you might not notice anything
20 年前 -
On Sunday's "Good Morning America Weekend Edition," Consumer Reports health editor Ronni Sandroff said that contrary to popular belief, price does not dictate a cream's power. "There was no correlation between effectiveness and price,&am...
A drop in breast cancer cases may be due to women eschewing Hormone Replacement Therapy (HRT), experts say.
Is a person hysterical if he or she complains of numbness in a limb but conventional tests reveal no underlying cause? A new study argues yes. While the term hysteria has fallen out of favor--replaced by the more reasonable sounding "conversion disor
International health experts called on Tuesday for rapid worldwide access to new cervical cancer vaccines that have the potential to save a quarter of a million lives a year.
In a study released in May, scientists at the Broad Institute scanned 20 million “letters” of genetic sequence from each of the human, chimpanzee, gorilla and macaque monkey genomes. Based on DNA differences, the researchers speculated that millions of ye
Doctors leading a global war on heart disease say they are "devastated" by the loss of a new drug they had expected to be an important weapon in the fight against high cholesterol. Pfizer had hoped to get federal approval next year to sell its
The announcement over the weekend that Pfizer had halted development of a potential blockbuster drug intended to treat heart disease dealt a major blow not only to the company, but to heart patients everywhere. Researchers had hoped the drug, torcetrapib,
Pfizer Inc. may fall short in convincing federal regulators that its painkiller Celebrex should receive expanded approval to treat children with a devastating form of arthritis, according to documents released Tuesday. Pfizer wants Food and Drug Admin
Pfizer Inc.'s new experimental heart drug is dead, but the dual approach the company was testing -- boosting good cholesterol while lowering the bad -- is very much alive, specialists said Monday. A drug already on the market, Niaspan, raises good chol
Pfizer Inc. may fall short in convincing federal regulators that its painkiller Celebrex should receive expanded approval to treat children with a devastating form of arthritis, according to documents released Tuesday. Pfizer wants Food and Drug Admini
The discovery that an experimental cholesterol drug is dangerous is a major setback for what has been considered one of the most promising new approaches to fighting the nation's leading killer, experts said yesterday. Pfizer Inc. abruptly announced la
Federal advisers recommended Wednesday that Pfizer Inc. be allowed to market the painkiller Celebrex as a treatment for children with a devastating form of arthritis, even though they split on whether it was safe.
Pfizer announced last night that it had discontinued research on its most important experimental drug, a treatment for heart disease. The decision is a stunning development that is likely to seriously damage the company’s prospects through the next decade
The news came to Pfizer’s chief scientist, Dr. John L. LaMattina, as he was showering at 7 a.m. Saturday: the company’s most promising experimental drug, intended to treat heart disease, actually caused an increase in deaths and heart problems. Eighty-two
A programme which encouraged women not to diet but to take part in exercise classes found significant improvements in health and mental well-being.
The disease may be the same for all ages, but everything about having it is different for its younger victims. Unlike older patients who are typically retired, confined to an assisted-living facility, and whose children are grown, young sufferers are in t
報主登入